Patterns of spontaneous reports on narcolepsy following administration of pandemic influenza vaccine; a case series of individual case safety reports in Eudravigilance

Vaccine

Volumn 34, Issue 41, 2016, Pages 4892-4897

  Gadroen, Kartini ^a,b   Straus, Sabine M J M ^a,b   Pacurariu, Alexandra ^a,b   Weibel, Daniel ^b   Kurz, Xavier ^c   Sturkenboom, Miriam C J M ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b MEDICINES EVALUATION BOARD   (Netherlands)

^c EUROPEAN MEDICINES AGENCY   (United Kingdom)

Author keywords

Brighton Collaboration; Eudravigilance; H1N1; Narcolepsy; Pandemic influenza vaccine; Signal detection

Indexed keywords

INFLUENZA VACCINE;

ADOLESCENT; ADULT; AGED; ARTICLE; BRAIN DAMAGE; CATAPLEXY; CHILD; DATA BASE; DESCRIPTIVE RESEARCH; DRUG SAFETY; FEMALE; FINLAND; GROUPS BY AGE; HUMAN; INFLUENZA VACCINATION; MAJOR CLINICAL STUDY; MALE; NARCOLEPSY; OUTCOME ASSESSMENT; PANDEMIC INFLUENZA; PRIORITY JOURNAL; QUALITY CONTROL; RETROSPECTIVE STUDY; SIGNAL DETECTION; SWEDEN; DRUG SURVEILLANCE PROGRAM; INFANT; MIDDLE AGED; NETHERLANDS; PRESCHOOL CHILD; UNITED KINGDOM; VACCINATION; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; FEMALE; FINLAND; HUMANS; INFANT; INFLUENZA VACCINES; MALE; MIDDLE AGED; NARCOLEPSY; NETHERLANDS; PHARMACOVIGILANCE; SWEDEN; UNITED KINGDOM; VACCINATION; YOUNG ADULT;

EID: 84990033504     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2016.08.062     Document Type: Article

References (21)

1. [1] Chan M. World now at the start of 2009 influenza pandemic. Statement to the press by WHO Director-General Dr Margaret Chan. Statement to the press by WHO Director-General Dr Margaret Chan. World Health Organization; 2009.
2. [2] ECDC. Enhanced monitoring of vaccine safety for 2009 pandemic vaccines.
3. [3] ECDC, Narcolepsy in association with pandemic influenza vaccination (a multi-country European epidemiological investigation). ECDC Technical Report, 2012, European Center for Disease prevention and Control (ECDC), Stockholm.
4. [4] Mereckiene, J., Cotter, S., Weber, J.T., Nicoll, A., D'Ancona, F., Lopalco, P.L., et al. Influenza A(H1N1)pdm09 vaccination policies and coverage in Europe. Euro surveillance: Bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2012, 17.
5. [5] European Medicines Agency policy on access to Eudravigilance data for medicinal products for human use. London: European Medicines Agency (EMA); 2015.
6. [6] Sturkenboom, M.C., The narcolepsy-pandemic influenza story: can the truth ever be unraveled?. Vaccine 33:Suppl. 2 (2015), B6–B13.
7. [7] EMA, Pandemic report and lessons learned; outcome of the European Medicines Agency activities during the (H1N1) flu pandemic. 2009, European Medicines Agency (EMA), London, 2011.
8. [8] VAESCO. VAESCO Background rates. Vaccine Adverse Event Surveillance and Communication (VAESCO).
9. [9] Kurz, X., Domergue, F., Slattery, J., Segec, A., Szmigiel, A., Hidalgo-Simon, A., Safety monitoring of Influenza A/H1N1 pandemic vaccines in Eudravigilance. Vaccine 29 (2011), 4378–4387.
10. [10] Kall, A., The Pandemrix – narcolepsy tragedy: how it started and what we know today. Acta Paediatr 102 (2013), 2–4.
11. [11] Yle Uutiset News. Minister calls for thorough examination of possible link between H1N1 and narcolepsy. Yle Finland's National Public Service Broadcasting Company; 2010.
12. [12] EMA. European Medicines Agency starts review of Pandemrix European Medicines Agency (EMA); 2010.
13. [13] Regulation (EU) no 1027/2012 of the European Parliament and of the Council of 25 October 2012 amending Regulation (EC) No 726/2004 as regards pharmacovigilance.
14. [14] Directive 2012/26/EU of the European Parliament and of the Council of 25 October 2012 amending Directive 2001/83/EC as regards pharmacovigilance.
15. [15] EMA. Good pharmacovigilance practices. London: European Medicines Agency (EMA).
16. [16] Group IEW. ICH harmonised tripartite guideline. Data elements for transmission of Individual Case Safety Reports E2B (R2); 2001.
17. [17] Heads of Medicines Agencies (HMA). EU Individual Case Safety Report (ICSR) Implementation Guide. Heads of Medicines Agencies (HMA), European Medicines Agency (EMA); 2014.
18. [18] Poli, F., Overeem, S., Lammers, G.J., Plazzi, G., Lecendreux, M., Bassetti, C.L., et al. Narcolepsy as an adverse event following immunization: case definition and guidelines for data collection, analysis and presentation. Vaccine 31 (2013), 994–1007.
19. [19] Brighton Collaboration. Resources. ABC Tool.
20. [20] Srba, J., Vlcek, J., Position and processing of adverse drug reactions directly submitted by patients to national regulatory authorities. Eur J Pharmacovigilance, 2014, 2.
21. [21] Dyer, C., UK government is to reconsider claims of children who developed narcolepsy after vaccination. BMJ, 347, 2013, f5645.